Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Jul;12(3):197-202.
doi: 10.1111/j.1542-474X.2007.00161.x.

Dofetilide-induced long QT and torsades de pointes

Mehmet K Aktas  1 , Abrar H Shah, Toshio Akiyama
Affiliations

Dofetilide-induced long QT and torsades de pointes

Mehmet K Aktas et al. Ann Noninvasive Electrocardiol. 2007 Jul.

Abstract

Dofetilide, a new class III antiarrhythmic agent, has been approved as an antiarrhythmic agent for the treatment of atrial fibrillation and atrial flutter. Dofetilide selectively inhibits the rapid component of the delayed rectifier potassium current resulting in a prolongation of the effective refractory period. Like other drugs that affect potassium currents, the prolonged QT interval occurring in the patients treated with dofetilide can be complicated by torsades de pointes. We report four cases of dofetilide-induced QT prolongation and torsades de pointes. We discuss the risk factors for the development of dofetilide-induced long QT and torsades de pointes and review the current literature.

PubMed Disclaimer

Figures

Figure 1
Figure 1
ECG 1. Patient 1. Twelve‐lead ECG showing sinus bradycardia, left atrial enlargement, left bundle branch block, and severe QT prolongation with a QTc of 0.8 seconds. Telemetry 1. Patient 1. Telemetry showing prolonged QTc and polymorphic ventricular tachycardia.
Figure 2
Figure 2
ECG 2. Patient 2. Before initiation of dofetilide. Twelve‐lead ECG showing atrial fibrillation, left bundle branch block, and QTc of 0.46 seconds.
Figure 3
Figure 3
ECG 3. Patient 2. After third dose of dofetilide. Twelve‐lead ECG showing NSR with ventricular capture spikes and a QTc of 0.57 seconds. Telemetry 2. Patient 2. Telemetry showing torsades de pointes.
Figure 4
Figure 4
ECG 4. Patient 3. Baseline before dofetilide. Twelve‐lead ECG showing atrial tachycardia with 2:1 atrioventricular block and a QTc of 0.43 seconds.
Figure 5
Figure 5
ECG 5. Patient 3. While on dofetilide and milrinone. Twelve‐lead ECG showing NSR with frequent ventricular premature contractions and a QTc of 0.67 seconds. Telemetry 3. Patient 3, Telemetry showing torsades de pointes.
Figure 6
Figure 6
ECG 6. Patient 4. Twelve‐lead ECG showing NSR followed by torsades de pointes. Telemetry 4. Patient 4. Telemetry showing torsades de pointes.
See this image and copyright information in PMC

References

    1. Mounsey JP, DiMarco JP. Cardiovascular drugs. Dofetilide. Circulation 2000;102:2665–2670. - PubMed
    1. Falk RH, Decara JM. Dofetilide: A new pure class III antiarrhythmic agent. Am Heart J 2000;140:697–706. - PubMed
    1. Rousseau MF, Massart PE, Van Eyll C, et al Cardiac and hemodynamic effects of intravenous dofetilide in patients with heart failure. Am J Cardiol 2001;87:1250–1254. - PubMed
    1. Singh S, Zoble RG, Yellen L, et al Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: The symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE‐D) study. Circulation 2000;102:2385–2390. - PubMed
    1. Guanzon AV, Crouch MA. Phase IV trial evaluating the effectiveness and safety of dofetilide. Ann Pharmacother 2004;38(7–8):1142–1147. - PubMed